Inovio surprised by Roche returning prostate cancer immunotherapy
This article was originally published in Scrip
The CEO of Inovio Pharmaceuticals has said the decision of its partner Roche to return rights to its prostate cancer immunotherapy "was a surprise to us". Dr Joseph Kim, Inovio's president and CEO, told Scrip that the company had no idea the collaboration was about to be terminated when Inovio reported Q3 results on 10 November and said it was expecting to begin Phase I trials of the preclinical DNA vaccine with Roche in 2015. "We were told on Friday [14 November] and announced it first thing Monday [17 November]," he said. "I believe it was a surprise to the Roche development team as well," he added.
You may also be interested in...
Deal Watch: Roche Aborts But Regeneron, Amgen and Pfizer Sign Up
Deal activity over the past seven days sees Roche knock back Inovio a second time, Regeneron plan for its future via an alliance with Adicet Bio, Amgen supplement its preclinical pipeline with a candidate from Advaxis, and Pfizer shore up its gene therapy ambitions with an acquisition.
Top-Selling Drugs 2022: Strong Growth In Blockbuster Ranks
COVID-19 products contributed almost a third to the global revenues from the top 20 best-selling drugs in 2022. However, strong growth was also seen for drugs across categories from immunology and cancer to HIV and cardiometabolic.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 10: Diversity, Equity And Inclusion
The acceleration of efforts to increase diversity among clinical trial subjects is expected to continue in 2023. Furthermore, many executives hope for greater inclusivity within companies, from new recruits to leadership.